Back to Team
    Eric Vela

    Eric Vela, PhD, MBA

    Principal

    Biotech CTO/CSO

    Eric Vela, PhD, MBA has over two decades experience growing highly successful gene therapy and viral vaccine programs that have driven innovation and novel process development and manufacturing platforms leading to the launch of new products for phase I clinical vaccine and immunotherapy trials. He has a plethora of experience ranging from in vivo efficacy and pre-clinical testing to vaccine process development and manufacturing at various Contract Research Organizations (CROs), Contract Development and Manufacturing Organizations (CDMOs) and seed stage start-up companies.

    Throughout his career, Eric has played a pivotal role in chemistry, manufacturing, and controls (CMC) activities which is critical to developing and launching new pharmaceutical products. His leadership has led to the development of novel manufacturing processes aimed at improving the vaccine production and purification processes and optimizing overall yield. Specifically, Eric has C-suite experience that revolves around CMC as it relates to gene therapy, viral vaccine, and viral oncolytic products.

    Career Accomplishments

    • •Served as the Chief Technical Officer (CTO) for a startup gene therapy company based in Boston.
    • •Led all manufacturing and process development activities associated with an AAV (Adeno-associated virus) novel capsid gene therapy technology associated with central nervous system (CNS) rare diseases and primary CNS lymphoma (PCNSL).
    • •Served as a Chief Technology Advisor for different companies with gene therapy and oncolytic virotherapy products.
    • •Served as the Executive Director for Process Development at a CDMO where he was responsible from expanding a team of 10 scientists and engineers to a team of 42 responsible for upstream and downstream operations ranging from small-scale bioreactors to a 1,000 L bioreactor in scale.
    • •Has process development and manufacturing production and purification experience in different therapeutic modalities including gene therapy vectors, oncolytic viruses, viral-based vaccines, antibodies, and proteins.
    • •Served as the Director of Virology at a Contract Research Organization (CRO) and was responsible for more than 50 GLP efficacy and tox nonhuman primate and small-mammal preclinical studies.
    • •Built and cultivated relationships with pharmaceutical companies and the Federal Drug Administration that contributed to increasing the CRO virology program's yearly business volume from $1-2M to $8-12M.

    Areas of Excellence

    • Viral vaccines and therapeutics and production modalities
    • Gene therapy products and production modalities
    • Oncolytic virotherapies
    • Process development and CGMP manufacturing
    • Vector design
    • Upstream production and downstream purification modalities
    • Transferring small-scale production/purification modalities to large-scale CGMP manufacturing
    • Bioreactor development
    • Strategic planning
    • CDMO management